Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,276 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,276 shares of Entrada Therapeutics stock in a transaction dated Wednesday, May 8th. The shares were acquired at an average price of $14.04 per share, with a total value of $31,955.04. Following the transaction, the director now owns 65,212 shares in the company, valued at approximately $915,576.48. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Entrada Therapeutics Price Performance

Shares of TRDA stock traded down $0.02 on Friday, hitting $14.34. The company's stock had a trading volume of 38,904 shares, compared to its average volume of 75,358. The stock has a market capitalization of $482.97 million, a price-to-earnings ratio of -55.15 and a beta of -0.38. Entrada Therapeutics, Inc. has a fifty-two week low of $10.62 and a fifty-two week high of $18.44. The firm's fifty day moving average price is $13.04 and its 200-day moving average price is $14.19.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.22). Entrada Therapeutics had a negative return on equity of 2.89% and a negative net margin of 5.18%. The company had revenue of $41.85 million during the quarter, compared to analyst estimates of $27.82 million. Analysts predict that Entrada Therapeutics, Inc. will post -1.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. TD Asset Management Inc increased its stake in shares of Entrada Therapeutics by 100.0% in the third quarter. TD Asset Management Inc now owns 119,254 shares of the company's stock worth $1,884,000 after purchasing an additional 59,627 shares during the period. SG Americas Securities LLC boosted its position in shares of Entrada Therapeutics by 27.7% in the fourth quarter. SG Americas Securities LLC now owns 11,714 shares of the company's stock valued at $177,000 after acquiring an additional 2,540 shares during the period. Strs Ohio grew its stake in shares of Entrada Therapeutics by 792.6% in the fourth quarter. Strs Ohio now owns 24,100 shares of the company's stock worth $363,000 after acquiring an additional 21,400 shares during the last quarter. Wellington Management Group LLP increased its position in Entrada Therapeutics by 2.6% during the third quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company's stock worth $16,521,000 after acquiring an additional 26,144 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new position in Entrada Therapeutics during the 3rd quarter valued at $44,000. Institutional investors and hedge funds own 86.39% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Entrada Therapeutics in a report on Monday, March 18th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.